155 related articles for article (PubMed ID: 23362323)
1. Functional analysis of genes in regions commonly amplified in high-grade serous and endometrioid ovarian cancer.
Davis SJ; Sheppard KE; Pearson RB; Campbell IG; Gorringe KL; Simpson KJ
Clin Cancer Res; 2013 Mar; 19(6):1411-21. PubMed ID: 23362323
[TBL] [Abstract][Full Text] [Related]
2. Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma.
Schraml P; Schwerdtfeger G; Burkhalter F; Raggi A; Schmidt D; Ruffalo T; King W; Wilber K; Mihatsch MJ; Moch H
Am J Pathol; 2003 Sep; 163(3):985-92. PubMed ID: 12937139
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.
Fejzo MS; Dering J; Ginther C; Anderson L; Ramos L; Walsh C; Karlan B; Slamon DJ
Genes Chromosomes Cancer; 2008 Oct; 47(10):873-83. PubMed ID: 18615678
[TBL] [Abstract][Full Text] [Related]
4. Amplification of 11q13 in ovarian carcinoma.
Brown LA; Kalloger SE; Miller MA; Shih IeM; McKinney SE; Santos JL; Swenerton K; Spellman PT; Gray J; Gilks CB; Huntsman DG
Genes Chromosomes Cancer; 2008 Jun; 47(6):481-9. PubMed ID: 18314909
[TBL] [Abstract][Full Text] [Related]
5. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas.
Moreno-Bueno G; Sánchez-Estévez C; Cassia R; Rodríguez-Perales S; Díaz-Uriarte R; Domínguez O; Hardisson D; Andujar M; Prat J; Matias-Guiu X; Cigudosa JC; Palacios J
Cancer Res; 2003 Sep; 63(18):5697-702. PubMed ID: 14522886
[TBL] [Abstract][Full Text] [Related]
6. Integrative prediction of gene function and platinum-free survival from genomic and epigenetic features in ovarian cancer.
Wrzeszczynski KO; Varadan V; Kamalakaran S; Levine DA; Dimitrova N; Lucito R
Methods Mol Biol; 2013; 1049():35-51. PubMed ID: 23913207
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of ovarian cancer amplification target ADRM1 leads to downregulation of GIPC1 and upregulation of RECK.
Fejzo MS; Ginther C; Dering J; Anderson L; Venkatesan N; Konecny G; Karlan B; Slamon DJ
Genes Chromosomes Cancer; 2011 Jun; 50(6):434-41. PubMed ID: 21432940
[TBL] [Abstract][Full Text] [Related]
9. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Tothill RW; Tinker AV; George J; Brown R; Fox SB; Lade S; Johnson DS; Trivett MK; Etemadmoghadam D; Locandro B; Traficante N; Fereday S; Hung JA; Chiew YE; Haviv I; ; Gertig D; DeFazio A; Bowtell DD
Clin Cancer Res; 2008 Aug; 14(16):5198-208. PubMed ID: 18698038
[TBL] [Abstract][Full Text] [Related]
10. Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.
Davis SJ; Sheppard KE; Anglesio MS; George J; Traficante N; Fereday S; Intermaggio MP; Menon U; Gentry-Maharaj A; Lubinski J; Gronwald J; Pearce CL; Pike MC; Wu A; Kommoss S; Pfisterer J; du Bois A; Hilpert F; Ramus SJ; Bowtell DD; Huntsman DG; Pearson RB; Simpson KJ; Campbell IG; Gorringe KL
Mol Cancer Ther; 2015 Jun; 14(6):1495-503. PubMed ID: 25852062
[TBL] [Abstract][Full Text] [Related]
11. Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma.
Lassus H; Staff S; Leminen A; Isola J; Butzow R
Gynecol Oncol; 2011 Jan; 120(1):11-7. PubMed ID: 20937525
[TBL] [Abstract][Full Text] [Related]
12. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas.
Brown LA; Irving J; Parker R; Kim H; Press JZ; Longacre TA; Chia S; Magliocco A; Makretsov N; Gilks B; Pollack J; Huntsman D
Gynecol Oncol; 2006 Feb; 100(2):264-70. PubMed ID: 16236351
[TBL] [Abstract][Full Text] [Related]
13. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas.
Wu R; Zhai Y; Fearon ER; Cho KR
Cancer Res; 2001 Nov; 61(22):8247-55. PubMed ID: 11719457
[TBL] [Abstract][Full Text] [Related]
14. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma.
Jazaeri AA; Lu K; Schmandt R; Harris CP; Rao PH; Sotiriou C; Chandramouli GV; Gershenson DM; Liu ET
Mol Carcinog; 2003 Feb; 36(2):53-9. PubMed ID: 12557260
[TBL] [Abstract][Full Text] [Related]
15. High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1.
Karlsson E; Waltersson MA; Bostner J; Pérez-Tenorio G; Olsson B; Hallbeck AL; Stål O
Genes Chromosomes Cancer; 2011 Oct; 50(10):775-87. PubMed ID: 21748818
[TBL] [Abstract][Full Text] [Related]
16. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
[TBL] [Abstract][Full Text] [Related]
17. Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform.
Tsuda H; Birrer MJ; Ito YM; Ohashi Y; Lin M; Lee C; Wong WH; Rao PH; Lau CC; Berkowitz RS; Wong KK; Mok SC
Cancer Genet Cytogenet; 2004 Dec; 155(2):97-107. PubMed ID: 15571795
[TBL] [Abstract][Full Text] [Related]
18. Interphase fluorescence in situ hybridization studies of ovarian adenocarcinomas using the midisatellite probe.
Kalir T; Eisberg A; Dottino P; Cohen C
Gynecol Oncol; 1999 Feb; 72(2):208-14. PubMed ID: 10021303
[TBL] [Abstract][Full Text] [Related]
19. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer.
Nanjundan M; Nakayama Y; Cheng KW; Lahad J; Liu J; Lu K; Kuo WL; Smith-McCune K; Fishman D; Gray JW; Mills GB
Cancer Res; 2007 Apr; 67(7):3074-84. PubMed ID: 17409414
[TBL] [Abstract][Full Text] [Related]
20. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas.
Birrer MJ; Johnson ME; Hao K; Wong KK; Park DC; Bell A; Welch WR; Berkowitz RS; Mok SC
J Clin Oncol; 2007 Jun; 25(16):2281-7. PubMed ID: 17538174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
